Tonix Pharmaceuticals receives Fast Track Designation for TNX-102 SL candidate in treating patients with Alzheimer's Aggression.
The FDA has already cleared the IND for the phase 2 Alzheimer's Aggression study and it's likely that it should be initiated before the end of the year.
Interim results from the phase 3 PTSD study, known as HONOR, are set to be reported in Q3 2018 which could act as a major catalyst for the stock.
With the phase 3 HONOR study coming under the required p-value necessary for early stopping, it is possible that regulatory approval for TNX-102 SL for PTSD could come sooner than expected.
Tonix Pharmaceuticals only has $19.3 million in cash as of March 31, 2018 which means that a near-term cash raise is highly likely.
Recently, Tonix Pharmaceuticals (TNXP) announced that the FDA had granted Fast Track Designation for TNX-102 SL for the treatment of Alzheimer's Agitation. Another reason to be bullish for the stock is because results